The efficacy of add-on ramelteon and subsequent dose reduction in benzodiazepine derivatives/Z-drugs for the treatment of sleep-related eating disorder and night eating syndrome: a retrospective analysis of consecutive patients.
benzodiazepine
delayed sleep-wake phase disorder
insomnia
night eating syndrome
nocturnal eating
ramelteon
sleep-related eating disorder
Journal
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
ISSN: 1550-9397
Titre abrégé: J Clin Sleep Med
Pays: United States
ID NLM: 101231977
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
12
3
2021
medline:
6
8
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
The objective of this study was to determine the efficacy of ramelteon in treating abnormal eating behavior in patients with sleep-related eating disorder and/or night eating syndrome. We retrospectively reviewed the medical records of patients with sleep-related eating disorder/night eating syndrome at the Yoyogi Sleep Disorder Center from November 2013 to November 2018. We categorized patients as ramelteon treatment responders when the frequency of nighttime eating per week decreased to less than half of that before treatment. Forty-nine patients were included in the analysis. The mean frequency of eating behavior (per week) (standard deviation) at baseline and post-ramelteon treatment was significantly different, at 5.3 (2.2) and 3.2 (3.0), respectively (P < .001). Twenty-one patients (42.9%) were classified as responders. Adverse events, all of which were mild daytime somnolence, were observed in 5 patients. There were significantly more individuals using benzodiazepine derivatives and Z-drugs before treatment and those with coexisting delayed sleep-wake phase disorder in the responder group than in the nonresponder group (P < .001 and P < .05, respectively). The mean benzodiazepine derivatives and Z-drugs dose significantly decreased from baseline to post-ramelteon treatment within the responder group (P < .05). This trend was not observed in the nonresponder group. Meanwhile, the sleep midpoint of patients with sleep-related eating disorder/night eating syndrome and delayed sleep-wake phase disorder did not significantly change after treatment. Our results indicate that ramelteon is a candidate treatment for sleep-related eating disorder/night eating syndrome. The effects of ramelteon might have occurred primarily through the reduction in benzodiazepine derivatives and Z-drugs rather than through the improvement in sleep-wake rhythm dysregulation.
Identifiants
pubmed: 33704048
doi: 10.5664/jcsm.9236
pmc: PMC8314616
doi:
Substances chimiques
Indenes
0
Pharmaceutical Preparations
0
Benzodiazepines
12794-10-4
ramelteon
901AS54I69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1475-1483Informations de copyright
© 2021 American Academy of Sleep Medicine.
Références
Sleep. 2003 Sep;26(6):657-61
pubmed: 14572116
Int J Eat Disord. 2010 Apr;43(3):241-7
pubmed: 19378289
Neurosci Lett. 2000 Nov 17;294(2):101-4
pubmed: 11058797
J Clin Psychiatry. 2008 Sep;69(9):1374-82
pubmed: 19193338
Sleep. 2000 Jun 15;23(4):553-8
pubmed: 10875562
J Clin Psychiatry. 1998 Jan;59(1):14-9
pubmed: 9491060
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344700
Case Rep Med. 2013;2013:867650
pubmed: 23762076
Psychiatry Res. 2015 Sep 30;229(1-2):577-9
pubmed: 26239768
Sleep Med X. 2020 Jul 18;2:100019
pubmed: 33870172
Eat Behav. 2008 Jan;9(1):62-72
pubmed: 18167324
J Clin Psychiatry. 2010 May;71(5):653-6
pubmed: 20492858
Sleep. 2006 Jun;29(6):814-9
pubmed: 16796220
J Clin Psychiatry. 2006 Nov;67(11):1729-34
pubmed: 17196052
J Clin Psychopharmacol. 2012 Jun;32(3):341-5
pubmed: 22544016
Sleep. 2006 Jul;29(7):949-54
pubmed: 16895263
Am J Psychiatry. 2006 May;163(5):893-8
pubmed: 16648332
Sleep Med. 2003 May;4(3):243-6
pubmed: 14592329
Eat Weight Disord. 2017 Dec;22(4):599-608
pubmed: 28929462
J Clin Psychiatry. 2016 Jul;77(7):e892-8
pubmed: 27464322
Sleep. 2020 Sep 14;43(9):
pubmed: 32227216
Int Clin Psychopharmacol. 2003 May;18(3):175-7
pubmed: 12702899
Int J Eat Disord. 2004 Jan;35(1):16-26
pubmed: 14705153
Open Neurol J. 2013 Jul 04;7:32-7
pubmed: 24133551
Sleep Med. 2012 Jun;13(6):686-90
pubmed: 22456111
Psychiatry Clin Neurosci. 2015 Jun;69(6):309-20
pubmed: 25495278
Neuropsychobiology. 1988;20(4):174-7
pubmed: 3255890
Am J Clin Nutr. 2008 Jun;87(6):1672-7
pubmed: 18541555
Sleep. 1996 Jan;19(1):36-40
pubmed: 8650460
J Clin Sleep Med. 2008 Oct 15;4(5):456-61
pubmed: 18853704
J Biol Rhythms. 1999 Feb;14(1):72-6
pubmed: 10036995
J Biol Rhythms. 2009 Feb;24(1):85-94
pubmed: 19150931
Psychosomatics. 1986 Jan;27(1):62-4
pubmed: 3952247
Sleep Med Rev. 2019 Dec;48:101214
pubmed: 31648145
Sleep Med. 2010 Jun;11(6):525-33
pubmed: 20483660
Eat Behav. 2013 Apr;14(2):199-203
pubmed: 23557820
J Clin Psychopharmacol. 2015 Feb;35(1):109-11
pubmed: 25478937
Eat Weight Disord. 2017 Sep;22(3):421-433
pubmed: 28573425
Arch Gen Psychiatry. 1990 Apr;47(4):343-51
pubmed: 2322085
J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):379
pubmed: 7897427
Clin Ther. 2016 Nov;38(11):2340-2372
pubmed: 27751669
J Clin Psychiatry. 2000 May;61(5):368-72
pubmed: 10847312
JAMA. 1999 Aug 18;282(7):657-63
pubmed: 10517719
Sleep. 1993 Aug;16(5):457-66
pubmed: 8104356
Chronobiol Int. 2019 Jun;36(6):770-783
pubmed: 30917702
Neurology. 2002 Mar 26;58(6):936-40
pubmed: 11914411
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
J Med Case Rep. 2017 Sep 28;11(1):275
pubmed: 28954634